flufenamic acid has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hetmann, M | 1 |
| Langner, C | 1 |
| Durmaz, V | 1 |
| Cespugli, M | 1 |
| Köchl, K | 1 |
| Krassnigg, A | 1 |
| Blaschitz, K | 1 |
| Groiss, S | 1 |
| Loibner, M | 1 |
| Ruau, D | 1 |
| Zatloukal, K | 1 |
| Gruber, K | 1 |
| Steinkellner, G | 1 |
| Gruber, CC | 1 |
1 other study available for flufenamic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification and validation of fusidic acid and flufenamic acid as inhibitors of SARS-CoV-2 replication using DrugSolver CavitomiX.
Topics: Acetylcholinesterase; COVID-19; Flufenamic Acid; Fusidic Acid; Humans; Papain; Peptide Hydrolases; S | 2023 |